Vemurafenib-Induced Eccrine Squamous Syringometaplasia

Lescoat, A; Droitcourt, Catherine; Stock, Nathalie; Gall, Florence Le; Dupuy, Adam J.

doi:10.1159/000351320

Cited by 9 publications

(6 citation statements)

References 16 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these cases, there was a very predominant eccrine squamous syringometaplasia (ESS) associated with the histological features of NEH resulting from damage to the sweat glands. ESS has been reported in the context of BRAFi‐treated patients with melanoma . These cases raise the possibility that it might represent a later stage of NEH more than direct drug toxicity.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Neutrophilic eccrine hidradenitis in two patients treated withBRAFinhibitors: a new cutaneous adverse event

et al. 2017

View full text Add to dashboard Cite

Neutrophilic eccrine hidradenitis (NEH) is a rare neutrophilic dermatosis, first described in patients undergoing chemotherapy for a malignant haemopathy. It has polymorphous clinical features and the association of both clinical and histological features is necessary to make a diagnosis. We report the first two cases of NEH in patients treated with a BRAF inhibitor (BRAFi), either dabrafenib or vemurafenib, for a stage IV metastatic melanoma. Disseminated erythematous plaques associated with fever and polyarthralgia occurred early after the initiation of treatment and were badly tolerated. Histological analyses confirmed the diagnosis of NEH. Symptoms disappeared a few days after the cessation of treatment and introduction of topical steroids. The replacement of one BRAFi with another is a therapeutic alternative as it is not necessarily associated with a relapse of NEH. NEH can be added to the spectrum of neutrophilic dermatoses induced by BRAFis. It occurs earlier (3-4 days) than previously described drug-induced NEH (9-12 days) and may be an earlier stage of eccrine squamous syringometaplasia, which has already been reported in the context of BRAFi-treated patients.

show abstract

Section: Discussionmentioning

confidence: 97%

“…ESS has been reported in the context of BRAFi-treated patients with melanoma. [13][14][15] These cases raise the possibility that it might represent a later stage of NEH more than direct drug toxicity.…”

Section: Discussionmentioning

confidence: 99%

Neutrophilic eccrine hidradenitis in two patients treated withBRAFinhibitors: a new cutaneous adverse event

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Although the specific cellular mechanisms to induce eccrine syringometaplasia have not been identified, it has numerous etiologic associations. Inflammation is the most common association, but it has also been linked to herpes virus infections and several chemotherapeutic drugs, most recently BRAF inhibitors vemurafenib and dabrafenib [9,11,12,13,14,15]. Based on 7 patients with a mean follow-up of 10 years, Brown et al [16] postulated that primary FM is a clonal disorder with limited or benign cutaneous manifestations.…”

Section: Discussionmentioning

confidence: 99%

A Case of Syringolymphoid Hyperplasia with Follicular Mucinosis

Behrens¹,

Jabcuga²,

Gardner³

et al. 2016

Dermatopathology

View full text Add to dashboard Cite

Syringolymphoid hyperplasia (SLH) is an extremely rare histopathological entity with fewer than 40 cases reported in the literature. SLH have been seen as both benign lesions and in association with T-cell lymphoproliferative lesions. A 20-year-old male presented with a solitary, infiltrated plaque on the left cheek initially diagnosed as a sebaceous carcinoma at an external institution. A repeat biopsy demonstrated prominent follicular mucinosis (FM), squamous metaplasia of the eccrine coils, and a moderately dense perieccrine lymphocytic infiltrate mimicking eccrine carcinoma. The lesion was subsequently diagnosed as SLH with associated FM, an entity that has been previously reported in 12 cases, including this current case. This case highlights the characteristic features of a rare entity, emphasizes the potential for misdiagnosis of SLH, and adds to the current series of SLH described in the literature.

show abstract

“…Keeping this in mind, it is important to investigate the concentration of cytostatics in sweat as a noninvasive procedure for subjects. This is significant not only for the estimation of drug treatment efficacy, but also for the explanation of some skin-related side effects, such as Grover's disease, which appears as a consequence of the concentration of chemotherapy drug metabolites in sweat [25,26]. However, the above-mentioned solutions demand complex and costly technological processes for manufacturing of the whole device, and the systems are not based on textile materials.…”

Section: Introductionmentioning

confidence: 99%

A Textile-Based Microfluidic Platform for the Detection of Cytostatic Drug Concentration in Sweat Samples

et al. 2020

View full text Add to dashboard Cite

This work presents a new multilayered microfluidic platform, manufactured using a rapid and cost-effective xurography technique, for the detection of drug concentrations in sweat. Textile fabrics made of cotton and polyester were used as a component of the platform, and they were positioned in the middle of the microfluidic device. In order to obtain a highly conductive textile, the fabrics were in situ coated with different amounts of polyaniline and titanium dioxide nanocomposite. This portable microfluidic platform comprises at least three layers of optically transparent and flexible PVC foils which were stacked one on top of the other. Electrical contacts were provided from the edge of the textile material when a microfluidic variable resistor was actually created. The platform was tested in plain artificial sweat and in artificial sweat with a dissolved cytostatic test drug, cyclophosphamide, of different concentrations. The proposed microfluidic device decreased in resistance when the sweat was applied. In addition, it could successfully detect different concentrations of cytostatic medication in the sweat, which could make it a very useful tool for simple, reliable, and fast diagnostics.

show abstract

Vemurafenib-Induced Eccrine Squamous Syringometaplasia

Cited by 9 publications

References 16 publications

Neutrophilic eccrine hidradenitis in two patients treated withBRAFinhibitors: a new cutaneous adverse event

Neutrophilic eccrine hidradenitis in two patients treated withBRAFinhibitors: a new cutaneous adverse event

A Case of Syringolymphoid Hyperplasia with Follicular Mucinosis

A Textile-Based Microfluidic Platform for the Detection of Cytostatic Drug Concentration in Sweat Samples

Contact Info

Product

Resources

About